BRIEF-Beigene Provides Update On Phase 2 Clinical Trial Of Zanubrutinib In Patients With Covid-19-Related Pulmonary Distress
BRIEF-Beigene Provides Update On Phase 2 Clinical Trial Of Zanubrutinib In Patients With Covid-19-Related Pulmonary Distress
Brief-BEI基因提供扎努布魯替尼治療新冠肺炎相關性肺窘迫患者第二期臨牀試驗的最新進展
April 8 (Reuters) - Beigene Ltd 6160.HK :
路透4月8日電-貝基恩有限公司6160.HK:
* BEIGENE PROVIDES UPDATE ON PHASE 2 CLINICAL TRIAL OF ZANUBRUTINIB IN PATIENTS WITH COVID-19-RELATED PULMONARY DISTRESS
*BEYGEN提供ZANUBRUTINIB治療新冠肺炎相關性肺窘迫患者的2期臨牀試驗的最新情況
* BEIGENE LTD - TRIAL DID NOT MEET CO-PRIMARY EFFICACY ENDPOINTS; NO NEW SAFETY SIGNALS IDENTIFIED
*BEYGEN LTD-試驗未達到聯合主要療效終點;沒有發現新的安全信號
* BEIGENE LTD - THERE WERE NO NEW OR ADDITIONAL SAFETY SIGNALS FOR ZANUBRUTINIB IDENTIFIED IN TRIAL
*BEYGEN LTD-在試驗中沒有發現ZANUBRUTINIB新的或額外的安全信號
Source text for Eikon: Further company coverage:
Eikon的源文本:進一步的公司報道:
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。